


Itk

Interleukin-2 inducible T-cell kinase;IL2 inducible T-cell kinase





HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

Itk (Interleukin-2-inducible T-cell kinase) is a member of the TEC family of kinases and is highly expressed in T cells. Itk plays a role in T-cell proliferation, differentiation, cytokine release and chemotaxis. Itk is functionally important for the development and effector function of Th2 and Th17 cells. Itk is an attractive target for the treatment of T-cell-mediated inflammatory diseases.

Itk Inhibitors & Modulators

BMS-509744 Cat. No.: HY-11092	GNE-4997 Cat. No.: HY-16984
Bioactivity: BMS-509744 is a potent and selective Itk inhibitor with an IC₅₀ of 19 nM. Purity: 98.02% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Bioactivity: GNE-4997 is a potent and selective ITK/TSK inhibitor. Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg
	
ITK inhibitor Cat. No.: HY-11066	PF-06465469 Cat. No.: HY-108691
Bioactivity: ITK inhibitor is a potent ITK inhibitor. Purity: 97.28% Clinical Data: No Development Reported Size: 5 mg	Bioactivity: PF-06465469 is a covalent inhibitor of ITK with an IC₅₀ of 2nM [1]. Purity: >98% Clinical Data: No Development Reported Size:
	
PRN694 Cat. No.: HY-12680	Vecabrutinib (SNS-062) Cat. No.: HY-109078
Bioactivity: PRN694 is a highly selective and potent covalent inhibitor of T cell kinase (ITK) and resting lymphocyte kinase (RLK) with IC₅₀s of 0.3 and 1.4 nM, respectively. Purity: 99.44% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	Bioactivity: Vecabrutinib is a potent, noncovalent BTK and ITK inhibitor, with K_d of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC₅₀ of 24 nM for ITK. Purity: 99.96% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
